Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Cross-sell driving ACV progress

Catapult Sports
3:27pm
November 18, 2026
CAT's 1H27 result was in line with consensus ACV and ahead at the Management EBITDA line. Closing ACV of US$145.2m was +25% on the pcp on a constant currency (c/c) basis (+18% ex-acquired ACV). Management EBITDA of ~US$16m (19.7% margin) was 3% above consensus. Performance metrics were sound (e.g. churn under 5%, Rule of 40 at 38%) and FCF (ex-transaction costs) was US$9.3m (vs US$8.2m in the pcp). >We make several adjustments to our estimates factoring in the 1H27 result, resulting in 6-8% downgrades to Management EBITDA over FY27-FY29F. We forecast ~US$165m in revenue and ~US$32m in Management EBITDA in FY27. Our price target is lowered to A$5.05 (from A$5.40) on these changes. We maintain our Buy recommendation.

A weak 1H27; reset underway but it will take time

Webjet Group Limited
3:27pm
November 18, 2026
WJL’s 1H27 result was weak and below expectations (underlying EBITDA A$7.0m, -51%), impacted by a weak trading environment, Virgin Australia’s commission cuts, the non-repeat of 1H26’s higher-than-usual variable revenue and lower conversion following website changes. New CEO Nicole Sheffield was candid: “This is not a good result… some of it was the market and some of it was us”. >No FY27 guidance was provided and 2H27 conditions are expected to remain uncertain. 2H27 has headwinds too, with a full six months of the lost Virgin Australia commission and the RBA’s card surcharging changes (from 1 October 2026; ~A$4m annualised). WJL is targeting A$10m of annualised cost savings (fully realised in FY28), but the CEO warned there is no quick fix. >We have materially lowered our FY27/28 EBITDA forecasts (-26.6%/-8.1%). We retain our HOLD rating with a new price target of A$0.30 (was A$0.40). In the absence of corporate activity, shareholders will need to be patient given the current challenges WJL needs to overcome.

Investing in book growth now for earnings later

Solvar
3:27pm
November 18, 2026
SVR’s 1Q27 trading update has highlighted a sustained acceleration in the group’s loan book growth, with the Australian loan book up 18.2% yoy driven by record originations of $163.9m (+72.7% yoy), taking the group’s book to ~$1.0bn. >FY27 remains a year of investment, with SVR flagging that upfront customer acquisition costs to support growth, investment in digital transformation, and a tougher macro backdrop will see FY27 Normalised NPAT of ~$21.0m (vs. MorgF $28.5m). Improved productivity benefits from FY27 investment are expected to flow through to NPAT in FY28 (with SVR targeting >$30m). >We cut our FY27/28 NPAT forecasts by -25%/-3% respectively, resulting in a revised price target of $1.65/sh. Overall, we look to SVR’s return to book growth as the key driver of earnings momentum into FY28-29, which should be further supported as near-term macro conditions ease. We therefore move to a BUY rating.

Coffer raid rescinded

Microba Life Sciences
3:27pm
November 18, 2026
Genetic Signatures (GSS) has walked away from the merger after Microba flagged it can’t fund completion without fresh capital. MAP has been in voluntary suspension since 17 Nov. >From the perspective of MAP, we never saw the deal as being about access to GSS’s 3base technology. It was about the balance sheet, and with that gone MAP is left in a precarious spot. >In our view, MAP faces real going concern risk without the merger or access to further capital. MAP remains in suspension to explore its options for alternative funding. We await further details around the outcome of this process. Until then, our recommendation and target price are under review.

Model update: Same scans, sooner recognition

Artrya
3:27pm
November 18, 2026
We have revised our revenue recognition assumptions. We previously modelled revenue waiting for the cash to land, whereas we now book at point of scan and the payment lag moves to the balance sheet. >FY27 revenue lifts to A$2m (from A$0.1m) and FY28 to A$12.9m (from A$3.4m). Same scans, same demand, just earlier on the P&L. None of this comes from HonorHealth, AYA’s new five-year Arizona contract, which we see as an early signal of things to come rather than a reason to lift numbers yet. >Pulling revenue forward is a modest positive for our valuation struck off FY31 sales. We maintain our Speculative Buy rating with an increased target price of A$4.70 (previously A$4.25).

FY26 result: Big Plus, but UK a small minus

Technology One
3:27pm
November 17, 2026
TNE’s FY26 result was in line with our expectations, with PBT of $217.6m (+20% YoY) (vs. MorgF $217.9m), and ARR +18% YoY to $652.1m (vs. MorgF $652m), both landing at the top end of guidance. Whilst no FY27 guidance was provided, TNE’s outlook commentary, Plus cross-sell traction, improved UK sales momentum, and renewed focus on regulated industries / Government verticals suggest TNE is on track to drive similar growth momentum into FY27, with its longer-term $1.0bn+ ARR target by FY30 firmly in sight. >Strong share price appreciation CYTD sees TNE trading on ~60x FY27F P/E. We move to a Hold, with a revised price target of $36.35, representing a 4.6% TSR.

International Spotlight

Richemont
3:27pm
November 17, 2026

FY26 result: In line, but a softer mix; cash is king

Elders
3:27pm
November 16, 2026
ELD’s FY26 underlying EBIT of A$187.7m (up 43%) was in line with our forecast. Beats in Rural Services, AIRR and lower Corporate costs (helped by dual systems costs moving below the line) offset misses in Crop Protection and Real Estate. Strong cashflow and gearing back into ELD’s target range were the highlights. >Outlook comments were positive. This was the first result under new CEO René Dedoncker. Growth in FY27 is expected given a full year of Delta, further synergies and SysMod margin benefits, partly offset by softer livestock prices and subdued residential real estate. We now forecast modest growth in FY27 and have lowered our forecasts. >After strong share price appreciation, we move to a HOLD rating (from ACCUMULATE) with a new price target of A$7.35 (A$7.20 previously).

Investing for growth amid renewed policy risk

SmartGroup
3:27pm
November 16, 2026
SIQ delivered what we saw as a positive trading update, with 3Q CY26 novated settlements up +31% and orders up +33% driving CY26 NPATA guidance of A$92m to A$94m, +6% ahead of our prior forecast and implying 2H26 NPATA up +20% yoy at the mid-point. >The excess revenue pipeline remains strong (A$17.9m), ongoing fuel price volatility has underpinned sustained demand for EVs (BEVs 72% of 3Q orders) and SIQ continues to reinvest into the business for future growth. >We move to a HOLD recommendation (from Accumulate) with a revised price target of A$10.45ps (from A$12.15ps). While CY26 is tracking ahead of expectations and SIQ continues to target a mid-40s EBITDA margin in CY27, growing negative sentiment towards the EV FBT concession and the potential for further changes present downside risk at current levels (~14x CY27 PE). We take this into account in setting our revised target price.

International Spotlight

Siemens
3:27pm
November 16, 2026
Siemens AG is a technology company which engages in the areas of automation and digitalisation. It operates through the following segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services.

News & insights

Explore how El Niño, crop conditions and supply risks may shape agricultural commodity investing and long-term portfolio opportunities.
Read more
Ella D'hage spent her QUT placement rotating through Morgans. Here's what she learned about trust, plain-English explanations and finding the right career path.
Read more
Why did tech shares fall in October 2026? Our market update covers the AI sell-off, oil surge, gold slide and ASX 200 gains, plus the outlook ahead.
Read more